Information Center
Xinkanghe's globally pioneering drug XKH001 has won the 2021 "Jishi Award" for one of the Top Ten Drug Innovation Breakthroughs.
Release time:
2022-04-20 22:55
On April 20, the results of the "2021 Drug Innovation for the Benefit of Humanity Award" organized by the Securities Times were announced. The XKH001 project, a globally pioneering (First in Class) Class 1 new drug independently developed by Xinkanghe, won the Top Ten Annual Drug Innovation Pioneer Award. As a leading innovative biotechnology company in China, Xinkanghe has been committed to the development of globally pioneering drugs for autoimmune diseases and immuno-oncology. This award is a recognition of the company's innovative research and development capabilities and technological platform.
This is the second consecutive year that the Securities Times has held the "Drug Innovation for the Benefit of Humanity Award" event. As a mainstream financial media, the Securities Times aims to leverage the advantages of mainstream media, gather various forces, and form industry consensus by selecting outstanding domestic drug innovation projects, excellent enterprises, and outstanding individuals, thereby promoting the development of China's innovative drug industry and encouraging enterprises and institutions to invest in the research and development of globally pioneering new drugs.
About the Company:
Xinkanghe is a clinical-stage innovative biopharmaceutical company founded by the renowned immunologist Academician Dong Chen. The company has the driving force for innovative drug development: a team of scientists with a strong foundation in immunology research, and a precise and efficient technological platform for translational medicine research that transforms basic target research into therapeutic drug development. The company is dedicated to the development of drugs targeting new or innovative combinations for tumors and autoimmune inflammatory diseases, leading the way in innovative immunotherapy antibody drugs, providing precise, high-quality, and efficient new treatments for patients with tumors and inflammatory diseases.
About XKH001:
XKH001 is the first monoclonal antibody drug targeting the IL-25 target independently developed by Xinkanghe, with global intellectual property rights. This project has obtained IND approvals from both China and the United States, making it the world's first IL-25 inhibitor approved and entering clinical trials. This drug will provide a new effective treatment option for patients with refractory or resistant inflammatory and allergic diseases worldwide. The approval of XKH001 also represents the rapid improvement of innovative research and development capabilities of Chinese biotechnology companies, with global FIC products entering the fast lane. We also look forward to XKH001 meeting the urgent clinical and patient needs with excellent data in clinical settings.
World's first, XKH001
Related News
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com